Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Vanda Pharmaceuticals
- Study ID
- NCT07090161
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Hypertension
- Uncontrolled Hypertension
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- iloperidone — DRUGiloperidone
- Placebo — DRUGplacebo comparator
Study Details
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension
Key Dates
- Start date
- Sep 15, 2025
- Status verified
- Jan 2026
- Primary completion
- Oct 31, 2026
- Completion
- Nov 30, 2026
Study Design
- Enrollment
- 240 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Experimental/Iloperidone
- Placebo Comparator: Placebo Comparator
Primary Outcome Measure
Change from baseline to treatment week 4 in SiSBP [ Time Frame: screening to treatment week 4 ]
Central Contacts
- Vanda Pharmaceuticals, Inc.202-734-3400
Locations (28)
Find similar trials in Phoenix, AZ
By condition
By specialty
Related Studies
- Effect of Electro-Acupuncture on Blood PressureRecruiting · University of California, Irvine · Irvine, California
- : Vascular Function in Health and DiseasePHASE1 · Recruiting · Russell Richardson · Salt Lake City, Utah
- A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionPHASE3 · Enrolling By Invitation · United Therapeutics · Phoenix, Arizona
- Blood Pressure Slopes and Ultrafiltration in Hemodialysis PatientsRecruiting · VA Office of Research and Development · Dallas, Texas